1h Free Analyst Time
The publisher has been monitoring the anti-thrombin III testing market and it is poised to grow by $ 161.48 mn during 2022-2026, accelerating at a CAGR of 7.73% during the forecast period. Our report on the anti-thrombin III testing market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by existence of tests related to anti-thrombin III, increase in the number of people with hypertension, and shift toward rapid diagnostics.
The anti-thrombin III testing market analysis includes the end-user segment and geographic landscape.
The publisher's anti-thrombin III testing market is segmented as below:
By End-user
- Hospitals
- Laboratories
- Academic and research institutes
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
This study identifies the presence of various blood clotting disorders as one of the prime reasons driving the anti-thrombin III testing market growth during the next few years. Also, rise in the geriatric population and prevalence of inherited anti-thrombin deficiency will lead to sizable demand in the market.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on anti-thrombin III testing market covers the following areas:
- Anti-thrombin III testing market sizing
- Anti-thrombin III testing market forecast
- Anti-thrombin III testing market industry analysis
The publisher's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading anti-thrombin III testing market vendors that include Abbott Laboratories, Beckman Coulter Inc., Becton Dickinson and Co., Bio Rad Laboratories Inc., Biron Health Group Inc., Danaher Corp., F. Hoffmann La Roche Ltd., Grifols SA, Invitae Corp., Merck KGaA, Meridian Bioscience Inc., Oy Medix Biochemica Ab, Randox Laboratories Ltd., Scripps Laboratories Inc., Sekisui Diagnostics LLC, Siemens AG, Sysmex Corp., Thermo Fisher Scientific Inc., Transasia Bio Medicals Ltd., and Werfenlife SA. Also, the anti-thrombin III testing market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary.
The publisher's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by End-user
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
Exhibits:
Executive Summary
The publisher recognizes the following companies as the key players in the global anti-thrombin III testing market: Abbott Laboratories, Beckman Coulter Inc., Becton Dickinson and Co., Bio Rad Laboratories Inc., Biron Health Group Inc., Danaher Corp., F. Hoffmann La Roche Ltd., Grifols SA, Invitae Corp., Merck KGaA, Meridian Bioscience Inc., Oy Medix Biochemica Ab, Randox Laboratories Ltd., Scripps Laboratories Inc., Sekisui Diagnostics LLC, Siemens AG, Sysmex Corp., Thermo Fisher Scientific Inc., Transasia Bio Medicals Ltd., and Werfenlife SA.Commenting on the report, an analyst from the publisher said: "The latest trend gaining momentum in the market is presence of various blood clotting disorders."
According to the report, one of the major drivers for this market is the existence of tests related to anti-thrombin III.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry.
The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Beckman Coulter Inc.
- Becton Dickinson and Co.
- Bio Rad Laboratories Inc.
- Biron Health Group Inc.
- Danaher Corp.
- F. Hoffmann La Roche Ltd.
- Grifols Sa
- Invitae Corp.
- Merck Kgaa
- Meridian Bioscience Inc.
- Oy Medix Biochemica Ab
- Randox Laboratories Ltd.
- Scripps Laboratories Inc.
- Sekisui Diagnostics LLC
- Siemens AG
- Sysmex Corp.
- Thermo Fisher Scientific Inc.
- Transasia Bio Medicals Ltd.
- Werfenlife Sa
